Investigators are encouraged to present their research at professional and scientific meetings. Below are publications based on NET-PD studies.

For more information on futility studies:
Neurology, Jan 2007; 68: 20-28 (A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease [pdf, 259KB]) (Permission granted by Lippincott Williams & Wilkins)

Neurology, Mar 2006; 66: 664-671 (A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease [pdf, 82KB]) (Permission granted by Lippincott Williams & Wilkins)

Neurology, Mar 2006; 66: 628-633 (Optimizing the ongoing search for new treatments for Parkinson disease: Using futility designs [pdf, 196KB]) (Permission granted by Lippincott Williams & Wilkins)

Neurology, Mar 2006; 66: 626-627 (Futility studies: Spending a little to save a lot [pdf, 268KB]) (Permission granted by Lippincott Williams & Wilkins)

Annals of Neurology, Feb 2005; 57:197-203 (A Responsive Outcome for Parkinson's Disease Neuroprotection Futility Studies [pdf, 95KB])

For more information on statistical issues:
Movement Disorders vol 19, Supp 9, 2004, pg S270 Abstract (Statistical Issues in Design of Phase II Futility Studies in Parkinson's Disease (PD)

Movement Disorders vol 19, Supp 9, 2004, pg S233 Abstract (Statistical Issues in Analysis of a large Simple Neuroprotection Trials (LST) in Parkinson's Disease (PD)

For more information on clinical trials infrastructure:
Movement Disorders vol 19, Supp 9, 2004, pg S198 Abstract (Do Clinical Trial Infrastructures Impact Enrollment Rates and Baseline Demographics in Early Parkinson's Disease (PD) Studies?)

PDFs require Adobe® Reader®.